Diener H.-C., Förderreuther S, Kropp P. et al., Therapie der Migräneattacke und Prophylaxe der Migräne, S1-Leitlinie, AWMF-Registernummer 030 – 057, Stand: 18. Oktober 2022, S. 39f; online abrufbar als pdf; zuletzt abgerufen am 12. April 2024
Diener H.-C., Förderreuther S, Kropp P. et al., Therapie der Migräneattacke und Prophylaxe der Migräne, S1-Leitlinie, AWMF-Registernummer 030 – 057, Stand: 18. Oktober 2022, S. 56; online abrufbar als pdf; zuletzt abgerufen am 26. April 2024
Diener H.-C., Förderreuther S, Kropp P. et al., Therapie der Migräneattacke und Prophylaxe der Migräne, S1-Leitlinie, AWMF-Registernummer 030 – 057, Stand: 18. Oktober 2022, S. 118-120; online abrufbar als pdf; zuletzt abgerufen am 12. April 2024
Ahmed N Mahmoud, Amgad Mentias, Akram Y Elgendy, Abdul Qazi, Amr F Barakat: Migraine and the risk of cardiovascular and cerebrovascular events: a meta-analysis of 16 cohort studies including 1 152 407 subjects. In: BMJ Open. Band8, Nr.3, 2018, ISSN2044-6055, S.e020498, doi:10.1136/bmjopen-2017-020498, PMID 29593023, PMC 5875642 (freier Volltext) – (bmj.com [abgerufen am 24. November 2019]).
cochrane.org
summaries.cochrane.org
K. Linde, G. Allais, B. Brinkhaus, E. Manheimer, A. Vickers, A. R. White: Acupuncture for migraine prophylaxis. In: Cochrane Database Syst Rev. Nr.1, 2009, S.CD001218 (cochrane.org).
S. Evers, A. May, G. Fritsche, P. Kropp, C. Lampl, V. Limmroth, V. Malzacher, S. Sandor, A. Straube, H. C. Diener: Akuttherapie und Prophylaxe der Migräne – Leitlinie der Deutschen Migräne- und Kopfschmerzgesellschaft und der Deutschen Gesellschaft für Neurologie. In: Nervenheilkunde. Band27, Nr.10, 2008, S.933–949 (dmkg.de [PDF]).
doi.org
L. J. Stovner, J. A. Zwart, K. Hagen, G. M. Terwindt, J. Pascual: Epidemiology of headache in Europe. In: Eur. J. Neurol. Band13, Nr.4, April 2006, S.333–345, doi:10.1111/j.1468-1331.2006.01184.x, PMID 16643310.
L. J. Stovner, K. Hagen, R. Jensen u. a.: The global burden of headache: a documentation of headache prevalence and disability worldwide. In: Cephalalgia. Band27, Nr.3, März 2007, S.193–210, doi:10.1111/j.1468-2982.2007.01288.x, PMID 17381554.
L. Kelman: The premonitory symptoms (prodrome): a tertiary care study of 893 migraineurs. In: Headache. Band44, Nr.9, Oktober 2004, S.865–872, doi:10.1111/j.1526-4610.2004.04168.x, PMID 15447695.
G. G. Schoonman, D. J. Evers, G. M. Terwindt, J. G. van Dijk, M. D. Ferrari: The prevalence of premonitory symptoms in migraine: a questionnaire study in 461 patients. In: Cephalalgia. Band26, Nr.10, Oktober 2006, S.1209–1213, doi:10.1111/j.1468-2982.2006.01195.x, PMID 16961788.
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. In: Cephalalgia. Band38, Nr.1, Januar 2018, S.1–211, doi:10.1177/0333102417738202.
A. May, P. J. Goadsby: The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. In: J. Cereb. Blood Flow Metab. Band19, Nr.2, Februar 1999, S.115–127, doi:10.1097/00004647-199902000-00001, PMID 10027765.
P. J. Goadsby, L. Edvinsson, R. Ekman: Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. In: Ann. Neurol. Band28, Nr.2, August 1990, S.183–187, doi:10.1002/ana.410280213.
P. Geppetti, J. G. Capone, M. Trevisani, P. Nicoletti, G. Zagli, M. R. Tola: CGRP and migraine: neurogenic inflammation revisited. In: J Headache Pain. Band6, Nr.2, April 2005, S.61–70, doi:10.1007/s10194-005-0153-6, PMID 16362644.
Y. Gursoy-Ozdemir, J. Qiu, N. Matsuoka u. a.: Cortical spreading depression activates and upregulates MMP-9. In: J. Clin. Invest. Band113, Nr.10, Mai 2004, S.1447–1455, doi:10.1172/JCI21227, PMID 15146242, PMC 406541 (freier Volltext).
H. C. Diener, M. Küper, T. Kurth: Migraine-associated risks and comorbidity. In: J. Neurol. Band255, Nr.9, September 2008, S.1290–1301, doi:10.1007/s00415-008-0984-6, PMID 18958572.
J. Haan, A. M. van den Maagdenberg, O. F. Brouwer, M. D. Ferrari: Migraine and epilepsy: genetically linked? In: Expert Rev Neurother. Band8, Nr.9, September 2008, S.1307–11, doi:10.1586/14737175.8.9.1307, PMID 18759542.
H. C. Diener, V. Pfaffenrath, L. Pageler, H. Peil, B. Aicher: The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. In: Cephalalgia. Band25, Nr.10, Oktober 2005, S.776–787, doi:10.1111/j.1468-2982.2005.00948.x, PMID 16162254.
D. Kudrow, H. M. Thomas, G. Ruoff u. a.: Valdecoxib for treatment of a single, acute, moderate to severe migraine headache. In: Headache. Band45, Nr.9, Oktober 2005, S.1151–1162, doi:10.1111/j.1526-4610.2005.00238.x, PMID 16178945.
S. J. Tepper, M. J. Stillman: Clinical and preclinical rationale for CGRP-receptor antagonists in the treatment of migraine. In: Headache. Band48, Nr.8, Dezember 2008, S.1259–1268, doi:10.1111/j.1526-4610.2008.01214.x.
Lanfranco Pellesi, Simona Guerzoni, Luigi Alberto Pini: Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date. In: Clinical Pharmacology in Drug Development. Band6, Nr.6, 2017, S.534–547, doi:10.1002/cpdd.345, PMID 28409893, PMC 5697612 (freier Volltext).
Philip R. Holland, Peter J. Goadsby: Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy. In: Neurotherapeutics. Band15, Nr.2, April 2018, S.304–312, doi:10.1007/s13311-018-0617-4, PMID 29556965, PMC 5935646 (freier Volltext).
K. R. Edwards, J. Norton, M. Behnke: Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headache. In: Headache. Band41, Nr.10, 2001, S.976–980, doi:10.1046/j.1526-4610.2001.01191.x, PMID 11903525.
T. Leniger, L. Pageler, P. Stude, H. C. Diener, V. Limmroth: Comparison of intravenous valproate with intravenous lysine-acetylsalicylic acid in acute migraine attacks. In: Headache. Band45, Nr.1, Januar 2005, S.42–46, doi:10.1111/j.1526-4610.2005.05009.x, PMID 15663612.
M. Bigal, F. Sheftell, S. Tepper, D. Tepper, T. W. Ho, A. Rapoport: A randomized double-blind study comparing rizatriptan, dexamethasone, and the combination of both in the acute treatment of menstrually related migraine. In: Headache. Band48, Nr.9, Oktober 2008, S.1286–1293, doi:10.1111/j.1526-4610.2008.01092.x, PMID 19031496.
I. Colman, B. W. Friedman, M. D. Brown u. a.: Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence. In: BMJ. Band336, Nr.7657, Juni 2008, S.1359–1361, doi:10.1136/bmj.39566.806725.BE, PMID 18541610, PMC 2427093 (freier Volltext).
S. D. Silberstein, F. G. Freitag, T. D. Rozen u. a.: Tramadol/acetaminophen for the treatment of acute migraine pain: findings of a randomized, placebo-controlled trial. In: Headache. Band45, Nr.10, 2005, S.1317–1327, doi:10.1111/j.1526-4610.2005.00264.x, PMID 16324164.
K. G. Shields, P. J. Goadsby: Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: a role in migraine? In: Brain. Band128, Pt 1, Januar 2005, S.86–97, doi:10.1093/brain/awh298, PMID 15574468.
S. Evers, J. Afra, A. Frese u. a.: EFNS guideline on the drug treatment of migraine - report of an EFNS task force. In: Eur. J. Neurol. Band13, Nr.6, Juni 2006, S.560–572, doi:10.1111/j.1468-1331.2006.01411.x, PMID 16796580.
J. Pascual, A. B. Caminero, V. Mateos u. a.: Preventing disturbing migraine aura with lamotrigine: an open study. In: Headache. Band44, Nr.10, 2004, S.1024–1028, doi:10.1111/j.1526-4610.2004.04198.x, PMID 15546267.
S. Silberstein, J. Saper, F. Berenson, M. Somogyi, K. McCague, J. D’Souza: Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study. In: Neurology. Band70, Nr.7, Februar 2008, S.548–555, doi:10.1212/01.wnl.0000297551.27191.70, PMID 18268247.
D. J. Goldstein, W. W. Offen, E. G. Klein u. a.: Lanepitant, an NK-1 antagonist, in migraine prevention. In: Cephalalgia. Band21, Nr.2, März 2001, S.102–106, doi:10.1046/j.1468-2982.2001.00161.x, PMID 11422091.
H. C. Diener, V. W. Rahlfs, U. Danesch: The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: reanalysis of efficacy criteria. In: Eur. Neurol. Band51, Nr.2, 2004, S.89–97, doi:10.1159/000076535, PMID 14752215 (karger.com).
H. Walach, W. Haeusler, T. Lowes u. a.: Classical homeopathic treatment of chronic headaches. In: Cephalalgia. Band17, Nr.2, April 1997, S.119–126; discussion 101, doi:10.1046/j.1468-2982.1997.1702119.x, PMID 9137850.
T. E. Whitmarsh, D. M. Coleston-Shields, T. J. Steiner: Double-blind randomized placebo-controlled study of homoeopathic prophylaxis of migraine. In: Cephalalgia. Band17, Nr.5, August 1997, S.600–604, doi:10.1046/j.1468-2982.1997.1705600.x, PMID 9251877.
D. B. Penzien, F. Andrasik, B. M. Freidenberg u. a.: Guidelines for trials of behavioral treatments for recurrent headache, first edition: American Headache Society Behavioral Clinical Trials Workgroup. In: Headache. 45 Suppl 2, Mai 2005, S.S110–S132, doi:10.1111/j.1526-4610.2005.4502004.x, PMID 15921503.
Y. Nestoriuc, A. Martin: Efficacy of biofeedback for migraine: a meta-analysis. In: Pain. Band128, Nr.1-2, März 2007, S.111–127, doi:10.1016/j.pain.2006.09.007, PMID 17084028.
L. Damen, J. K. Bruijn, A. P. Verhagen, M. Y. Berger, J. Passchier, B. W. Koes: Symptomatic treatment of migraine in children: a systematic review of medication trials. In: Pediatrics. Band116, Nr.2, August 2005, S.e295–e302, doi:10.1542/peds.2004-2742, PMID 16061583.
K. Ahonen, M. L. Hämäläinen, M. Eerola, K. Hoppu: A randomized trial of rizatriptan in migraine attacks in children. In: Neurology. Band67, Nr.7, Oktober 2006, S.1135–1140, doi:10.1212/01.wnl.0000238179.79888.44, PMID 16943370.
D. W. Lewis, P. Winner, A. D. Hershey, W. W. Wasiewski: Efficacy of zolmitriptan nasal spray in adolescent migraine. In: Pediatrics. Band120, Nr.2, August 2007, S.390–396, doi:10.1542/peds.2007-0085, PMID 17671066.
L. Damen, J. Bruijn, A. P. Verhagen, M. Y. Berger, J. Passchier, B. W. Koes: Prophylactic treatment of migraine in children. Part 2. A systematic review of pharmacological trials. In: Cephalalgia. Band26, Nr.5, Mai 2006, S.497–505, doi:10.1111/j.1468-2982.2005.01047.x, PMID 16674757.
L. Damen, J. Bruijn, B. W. Koes, M. Y. Berger, J. Passchier, A. P. Verhagen: Prophylactic treatment of migraine in children. Part 1. A systematic review of non-pharmacological trials. In: Cephalalgia. Band26, Nr.4, April 2006, S.373–383, doi:10.1111/j.1468-2982.2005.01046.x, PMID 16556238.
Ahmed N Mahmoud, Amgad Mentias, Akram Y Elgendy, Abdul Qazi, Amr F Barakat: Migraine and the risk of cardiovascular and cerebrovascular events: a meta-analysis of 16 cohort studies including 1 152 407 subjects. In: BMJ Open. Band8, Nr.3, 2018, ISSN2044-6055, S.e020498, doi:10.1136/bmjopen-2017-020498, PMID 29593023, PMC 5875642 (freier Volltext) – (bmj.com [abgerufen am 24. November 2019]).
IGeL-Monitor: Biofeedback bei Migräne. abgerufen am 14. Januar 2019. Mehr zur Begründung der Bewertung im Ergebnisbericht. (PDF; 113 kB) abgerufen am 14. Januar 2019.
karger.com
content.karger.com
H. C. Diener, J. P. Jansen, A. Reches, J. Pascual, D. Pitei, T. J. Steiner: Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison. In: Eur. Neurol. Band47, Nr.2, 2002, S.99–107, PMID 11844898 (karger.com).
H. C. Diener, V. W. Rahlfs, U. Danesch: The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: reanalysis of efficacy criteria. In: Eur. Neurol. Band51, Nr.2, 2004, S.89–97, doi:10.1159/000076535, PMID 14752215 (karger.com).
M. Obermann, Z. Katsarava: Epidemiology of unilateral headaches. In: Expert Rev Neurother. 8(9), Sep 2008, S. 1313–1320. PMID 18759543.
L. J. Stovner, J. A. Zwart, K. Hagen, G. M. Terwindt, J. Pascual: Epidemiology of headache in Europe. In: Eur. J. Neurol. Band13, Nr.4, April 2006, S.333–345, doi:10.1111/j.1468-1331.2006.01184.x, PMID 16643310.
J. D. Bartleson, F. M. Cutrer: Migraine update. Diagnosis and treatment. In: Minn Med. Band93, Nr.5, Mai 2010, S.36–41, PMID 20572569.
L. J. Stovner, K. Hagen, R. Jensen u. a.: The global burden of headache: a documentation of headache prevalence and disability worldwide. In: Cephalalgia. Band27, Nr.3, März 2007, S.193–210, doi:10.1111/j.1468-2982.2007.01288.x, PMID 17381554.
W. F. Stewart, M. S. Linet, D. D. Celentano, M. Van Natta, D. Ziegler: Age- and sex-specific incidence rates of migraine with and without visual aura. In: Am. J. Epidemiol. Band134, Nr.10, November 1991, S.1111–1120, PMID 1746521.
R. B. Lipton, W. F. Stewart, D. D. Celentano, M. L. Reed: Undiagnosed migraine headaches. A comparison of symptom-based and reported physician diagnosis. In: Arch Intern Med. Band152, Nr.6, Juni 1992, S.1273–1278, PMID 1599358.
L. Kelman: The premonitory symptoms (prodrome): a tertiary care study of 893 migraineurs. In: Headache. Band44, Nr.9, Oktober 2004, S.865–872, doi:10.1111/j.1526-4610.2004.04168.x, PMID 15447695.
G. G. Schoonman, D. J. Evers, G. M. Terwindt, J. G. van Dijk, M. D. Ferrari: The prevalence of premonitory symptoms in migraine: a questionnaire study in 461 patients. In: Cephalalgia. Band26, Nr.10, Oktober 2006, S.1209–1213, doi:10.1111/j.1468-2982.2006.01195.x, PMID 16961788.
J. Todd: The syndrome of Alice in Wonderland. In: Can Med Assoc J. Band73, Nr.9, November 1955, S.701–704, PMID 13304769, PMC 1826192 (freier Volltext).
P. T. Fukui, T. R. Gonçalves, C. G. Strabelli u. a.: Trigger factors in migraine patients. In: Arq Neuropsiquiatr. Band66, 3A, September 2008, S.494–499, PMID 18813707 (scielo.br).
A. May, P. J. Goadsby: The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. In: J. Cereb. Blood Flow Metab. Band19, Nr.2, Februar 1999, S.115–127, doi:10.1097/00004647-199902000-00001, PMID 10027765.
L. L. Thomsen, J. Olesen: Nitric oxide theory of migraine. In: Clin. Neurosci. Band5, Nr.1, 1998, S.28–33, PMID 9523055.
M. A. Moskowitz, K. Nozaki, R. P. Kraig: Neocortical spreading depression provokes the expression of c-fos protein-like immunoreactivity within trigeminal nucleus caudalis via trigeminovascular mechanisms. In: J. Neurosci. Band13, Nr.3, März 1993, S.1167–1177, PMID 8382735.
M. A. Moskowitz: Neurogenic inflammation in the pathophysiology and treatment of migraine. In: Neurology. Band43, 6 Suppl 3, Juni 1993, S.S16–S20, PMID 8389008.
P. Geppetti, J. G. Capone, M. Trevisani, P. Nicoletti, G. Zagli, M. R. Tola: CGRP and migraine: neurogenic inflammation revisited. In: J Headache Pain. Band6, Nr.2, April 2005, S.61–70, doi:10.1007/s10194-005-0153-6, PMID 16362644.
Y. Gursoy-Ozdemir, J. Qiu, N. Matsuoka u. a.: Cortical spreading depression activates and upregulates MMP-9. In: J. Clin. Invest. Band113, Nr.10, Mai 2004, S.1447–1455, doi:10.1172/JCI21227, PMID 15146242, PMC 406541 (freier Volltext).
H. C. Diener, M. Küper, T. Kurth: Migraine-associated risks and comorbidity. In: J. Neurol. Band255, Nr.9, September 2008, S.1290–1301, doi:10.1007/s00415-008-0984-6, PMID 18958572.
J. Haan, A. M. van den Maagdenberg, O. F. Brouwer, M. D. Ferrari: Migraine and epilepsy: genetically linked? In: Expert Rev Neurother. Band8, Nr.9, September 2008, S.1307–11, doi:10.1586/14737175.8.9.1307, PMID 18759542.
H. C. Diener, V. Pfaffenrath, L. Pageler, H. Peil, B. Aicher: The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. In: Cephalalgia. Band25, Nr.10, Oktober 2005, S.776–787, doi:10.1111/j.1468-2982.2005.00948.x, PMID 16162254.
J. Goldstein u. a.: Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine: results from a multicenter, double-blind, randomized, parallel-group, single-dose, placebo-controlled study. In: Headache. 46, 2006, S. 444–453. PMID 16618262
D. Kudrow, H. M. Thomas, G. Ruoff u. a.: Valdecoxib for treatment of a single, acute, moderate to severe migraine headache. In: Headache. Band45, Nr.9, Oktober 2005, S.1151–1162, doi:10.1111/j.1526-4610.2005.00238.x, PMID 16178945.
S. Silberstein, S. Tepper, J. Brandes u. a.: Randomized, placebo-controlled trial of rofecoxib in the acute treatment of migraine. In: Neurology. Band62, Nr.9, Mai 2004, S.1552–1557, PMID 15136680.
Lanfranco Pellesi, Simona Guerzoni, Luigi Alberto Pini: Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date. In: Clinical Pharmacology in Drug Development. Band6, Nr.6, 2017, S.534–547, doi:10.1002/cpdd.345, PMID 28409893, PMC 5697612 (freier Volltext).
Philip R. Holland, Peter J. Goadsby: Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy. In: Neurotherapeutics. Band15, Nr.2, April 2018, S.304–312, doi:10.1007/s13311-018-0617-4, PMID 29556965, PMC 5935646 (freier Volltext).
P. Tfelt-Hansen, P. R. Saxena, C. Dahlöf u. a.: Ergotamine in the acute treatment of migraine: a review and European consensus. In: Brain. 123 ( Pt 1), Januar 2000, S.9–18, PMID 10611116.
H. C. Diener, J. P. Jansen, A. Reches, J. Pascual, D. Pitei, T. J. Steiner: Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison. In: Eur. Neurol. Band47, Nr.2, 2002, S.99–107, PMID 11844898 (karger.com).
K. R. Edwards, J. Norton, M. Behnke: Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headache. In: Headache. Band41, Nr.10, 2001, S.976–980, doi:10.1046/j.1526-4610.2001.01191.x, PMID 11903525.
T. Leniger, L. Pageler, P. Stude, H. C. Diener, V. Limmroth: Comparison of intravenous valproate with intravenous lysine-acetylsalicylic acid in acute migraine attacks. In: Headache. Band45, Nr.1, Januar 2005, S.42–46, doi:10.1111/j.1526-4610.2005.05009.x, PMID 15663612.
M. Bigal, F. Sheftell, S. Tepper, D. Tepper, T. W. Ho, A. Rapoport: A randomized double-blind study comparing rizatriptan, dexamethasone, and the combination of both in the acute treatment of menstrually related migraine. In: Headache. Band48, Nr.9, Oktober 2008, S.1286–1293, doi:10.1111/j.1526-4610.2008.01092.x, PMID 19031496.
I. Colman, B. W. Friedman, M. D. Brown u. a.: Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence. In: BMJ. Band336, Nr.7657, Juni 2008, S.1359–1361, doi:10.1136/bmj.39566.806725.BE, PMID 18541610, PMC 2427093 (freier Volltext).
S. D. Silberstein, F. G. Freitag, T. D. Rozen u. a.: Tramadol/acetaminophen for the treatment of acute migraine pain: findings of a randomized, placebo-controlled trial. In: Headache. Band45, Nr.10, 2005, S.1317–1327, doi:10.1111/j.1526-4610.2005.00264.x, PMID 16324164.
K. G. Shields, P. J. Goadsby: Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: a role in migraine? In: Brain. Band128, Pt 1, Januar 2005, S.86–97, doi:10.1093/brain/awh298, PMID 15574468.
H. Nishio, Y. Nagakura, T. Segawa: Interactions of carteolol and other beta-adrenoceptor blocking agents with serotonin receptor subtypes. In: Arch Int Pharmacodyn Ther. Band302, 1989, S.96–106, PMID 2576893.
V. Johannsson, L. R. Nilsson, T. Widelius u. a.: Atenolol in migraine prophylaxis a double-blind cross-over multicentre study. In: Headache. Band27, Nr.7, Juli 1987, S.372–374, PMID 3308768.
R. M. Gallagher, R. A. Stagliano, C. Sporazza: Timolol maleate, a beta blocker, in the treatment of common migraine headache. In: Headache. Band27, Nr.2, Februar 1987, S.84–86, PMID 3553070.
S. D. Silberstein: Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. In: Neurology. Band55, Nr.6, September 2000, S.754–762, PMID 10993991.
S. Evers, J. Afra, A. Frese u. a.: EFNS guideline on the drug treatment of migraine - report of an EFNS task force. In: Eur. J. Neurol. Band13, Nr.6, Juni 2006, S.560–572, doi:10.1111/j.1468-1331.2006.01411.x, PMID 16796580.
J. Pascual, A. B. Caminero, V. Mateos u. a.: Preventing disturbing migraine aura with lamotrigine: an open study. In: Headache. Band44, Nr.10, 2004, S.1024–1028, doi:10.1111/j.1526-4610.2004.04198.x, PMID 15546267.
S. Silberstein, J. Saper, F. Berenson, M. Somogyi, K. McCague, J. D’Souza: Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study. In: Neurology. Band70, Nr.7, Februar 2008, S.548–555, doi:10.1212/01.wnl.0000297551.27191.70, PMID 18268247.
K. M. Welch, D. J. Ellis, P. A. Keenan: Successful migraine prophylaxis with naproxen sodium. In: Neurology. Band35, Nr.9, September 1985, S.1304–1310, PMID 4022376.
D. J. Goldstein, W. W. Offen, E. G. Klein u. a.: Lanepitant, an NK-1 antagonist, in migraine prevention. In: Cephalalgia. Band21, Nr.2, März 2001, S.102–106, doi:10.1046/j.1468-2982.2001.00161.x, PMID 11422091.
H. C. Diener, V. W. Rahlfs, U. Danesch: The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: reanalysis of efficacy criteria. In: Eur. Neurol. Band51, Nr.2, 2004, S.89–97, doi:10.1159/000076535, PMID 14752215 (karger.com).
R. B. Lipton, H. Göbel, K. M. Einhäupl, K. Wilks, A. Mauskop: Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. In: Neurology. Band63, Nr.12, Dezember 2004, S.2240–2244, PMID 15623680.
H. Walach, W. Haeusler, T. Lowes u. a.: Classical homeopathic treatment of chronic headaches. In: Cephalalgia. Band17, Nr.2, April 1997, S.119–126; discussion 101, doi:10.1046/j.1468-2982.1997.1702119.x, PMID 9137850.
T. E. Whitmarsh, D. M. Coleston-Shields, T. J. Steiner: Double-blind randomized placebo-controlled study of homoeopathic prophylaxis of migraine. In: Cephalalgia. Band17, Nr.5, August 1997, S.600–604, doi:10.1046/j.1468-2982.1997.1705600.x, PMID 9251877.
D. B. Penzien, F. Andrasik, B. M. Freidenberg u. a.: Guidelines for trials of behavioral treatments for recurrent headache, first edition: American Headache Society Behavioral Clinical Trials Workgroup. In: Headache. 45 Suppl 2, Mai 2005, S.S110–S132, doi:10.1111/j.1526-4610.2005.4502004.x, PMID 15921503.
Y. Nestoriuc, A. Martin: Efficacy of biofeedback for migraine: a meta-analysis. In: Pain. Band128, Nr.1-2, März 2007, S.111–127, doi:10.1016/j.pain.2006.09.007, PMID 17084028.
L. Damen, J. K. Bruijn, A. P. Verhagen, M. Y. Berger, J. Passchier, B. W. Koes: Symptomatic treatment of migraine in children: a systematic review of medication trials. In: Pediatrics. Band116, Nr.2, August 2005, S.e295–e302, doi:10.1542/peds.2004-2742, PMID 16061583.
K. Ahonen, M. L. Hämäläinen, M. Eerola, K. Hoppu: A randomized trial of rizatriptan in migraine attacks in children. In: Neurology. Band67, Nr.7, Oktober 2006, S.1135–1140, doi:10.1212/01.wnl.0000238179.79888.44, PMID 16943370.
D. W. Lewis, P. Winner, A. D. Hershey, W. W. Wasiewski: Efficacy of zolmitriptan nasal spray in adolescent migraine. In: Pediatrics. Band120, Nr.2, August 2007, S.390–396, doi:10.1542/peds.2007-0085, PMID 17671066.
L. Damen, J. Bruijn, A. P. Verhagen, M. Y. Berger, J. Passchier, B. W. Koes: Prophylactic treatment of migraine in children. Part 2. A systematic review of pharmacological trials. In: Cephalalgia. Band26, Nr.5, Mai 2006, S.497–505, doi:10.1111/j.1468-2982.2005.01047.x, PMID 16674757.
L. Damen, J. Bruijn, B. W. Koes, M. Y. Berger, J. Passchier, A. P. Verhagen: Prophylactic treatment of migraine in children. Part 1. A systematic review of non-pharmacological trials. In: Cephalalgia. Band26, Nr.4, April 2006, S.373–383, doi:10.1111/j.1468-2982.2005.01046.x, PMID 16556238.
Ahmed N Mahmoud, Amgad Mentias, Akram Y Elgendy, Abdul Qazi, Amr F Barakat: Migraine and the risk of cardiovascular and cerebrovascular events: a meta-analysis of 16 cohort studies including 1 152 407 subjects. In: BMJ Open. Band8, Nr.3, 2018, ISSN2044-6055, S.e020498, doi:10.1136/bmjopen-2017-020498, PMID 29593023, PMC 5875642 (freier Volltext) – (bmj.com [abgerufen am 24. November 2019]).
P. T. Fukui, T. R. Gonçalves, C. G. Strabelli u. a.: Trigger factors in migraine patients. In: Arq Neuropsiquiatr. Band66, 3A, September 2008, S.494–499, PMID 18813707 (scielo.br).
Ahmed N Mahmoud, Amgad Mentias, Akram Y Elgendy, Abdul Qazi, Amr F Barakat: Migraine and the risk of cardiovascular and cerebrovascular events: a meta-analysis of 16 cohort studies including 1 152 407 subjects. In: BMJ Open. Band8, Nr.3, 2018, ISSN2044-6055, S.e020498, doi:10.1136/bmjopen-2017-020498, PMID 29593023, PMC 5875642 (freier Volltext) – (bmj.com [abgerufen am 24. November 2019]).
zeno.org
images.zeno.org
Wilhelm Pape, Max Sengebusch (Bearb.): Handwörterbuch der griechischen Sprache. 3. Auflage, 6. Abdruck. Vieweg & Sohn, Braunschweig 1914 (zeno.org [abgerufen am 12. September 2019]).